Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY - Get Free Report) shares gapped up prior to trading on Monday . The stock had previously closed at $24.50, but opened at $26.38. Chugai Pharmaceutical shares last traded at $25.64, with a volume of 1,382 shares.
Chugai Pharmaceutical Price Performance
The firm's fifty day simple moving average is $27.04 and its 200 day simple moving average is $24.15. The company has a market capitalization of $86.52 billion, a price-to-earnings ratio of 32.46 and a beta of 0.68.
Chugai Pharmaceutical (OTCMKTS:CHGCY - Get Free Report) last announced its earnings results on Thursday, April 24th. The company reported $0.19 earnings per share (EPS) for the quarter. The company had revenue of $1.89 billion for the quarter. Chugai Pharmaceutical had a net margin of 33.56% and a return on equity of 21.71%. Equities research analysts forecast that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.74 earnings per share for the current fiscal year.
Chugai Pharmaceutical Company Profile
(
Get Free Report)
Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.
See Also
Before you consider Chugai Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chugai Pharmaceutical wasn't on the list.
While Chugai Pharmaceutical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
